Little is known about what causes or increases someone’s risk of developing ALS. Researchers think it’s only around 50% genetic, indicating that there are strong environmental and lifestyle risk factors affecting disease development. But very few of these risk factors have been identified.
Flanked by a bipartisan group of teary-eyed lawmakers, Minnesota Gov. Tim Walz on Monday signed into law a plan to fund $20 million in research into treating and curing ALS, a disease that is currently incurable and always fatal.
With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients.
The president and chief executive officer of The ALS Association discussed how prevention is being talked about in the ALS community and why it’s no longer a far-off reality.
Results from a single clinical trial of an experimental drug for ALS developed by Amylyx Pharmaceuticals “may not be sufficiently persuasive” to support approval, according to a review of the drug posted Monday by officials with the Food and Drug Administration.
Biogen Inc. and Ionis Pharmaceuticals Inc. on Monday said they are ending development of a drug candidate for a form of amyotrophic lateral sclerosis, the paralyzing condition commonly known as Lou Gehrig's disease, following the failure of a Phase 1 study.